BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine

Trial Profile

BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Vemurafenib (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms BRIM-3
  • Sponsors Roche
  • Most Recent Events

    • 01 Oct 2017 Results (data cut off 14 August 2015) of final overall survival data including landmark analyses at 3 and 4 years published in the Annals of Oncology
    • 12 Sep 2017 Results of pool data from four trials (BRIM-2, BRIM-3, BRIM-7, and coBRIM) assessing impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib, were presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results of an exploratory analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM studies presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top